Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> In conclusion, we found that galectin-3 and MMP-2 were significantly associated with global cardiac fibrosis in HFpEF patients.
|
30413105 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Conclusions Gal-3 and ST2 are considered as a reflection of cardiac fibrosis and remodeling.
|
31622239 |
2020 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Galectin-3, a β-galactoside binding lectin, has been described as a mediator of cardiac fibrosis in experimental studies and as a risk factor associated with cardiovascular events in subjects with heart failure.
|
26312551 |
2015 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3), indicating cardiac fibrosis, is a documented biomarker of prognosis in HF.
|
28318874 |
2017 |
Cardiac fibrosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Linaclotide ameliorated renal inflammation and fibrosis and cardiac fibrosis, as well as decreased the expression of collagen I, transforming growth factor-β, galectin-3 (Gal-3) and ST2 genes.
|
31411705 |
2020 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
BACKGROUND Galectin-3 and soluble suppression of tumorigenicity-2 (sST2) are promising biomarkers of cardiac fibrosis and ventricular remodeling.
|
30039808 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We assessed the predictive ability of circulating biomarkers involved in collagen synthesis (procollagen type I N-terminal propeptide [PINP], and procollagen type III N-terminal propeptide [PIIINP], collagen degradation (c-terminal telopeptide of collagen type I [CTx] and mediators of cardiac fibrosis (Galectin-3 and soluble suppression of tumorigenicity 2 protein or sST2) as prognosis markers in 182 subjects with chronic heart failure (HF).
|
30179616 |
2019 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Galectin-3 plays an important role in the regulation of inflammation, development of cardiac fibrosis, and remodelling.
|
28150280 |
2017 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
It remains unclear whether Gal-3 interacts with K<sub>Ca</sub>3.1 leading to cardiac fibrosis in the setting of βAR activation.
|
31838908 |
2020 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3) is an important mediator of cardiac fibrosis, particularly in heart failure.
|
28525549 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Experimental research has shown that galectin-3 directly induces pathologic remodeling of the heart, and is therefore considered a culprit protein in the development of cardiac fibrosis in HF, with potentially relevant clinical implications.
|
29153203 |
2018 |
Cardiac fibrosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Dahl salt-sensitive hypertensive rats with diastolic dysfunction showed increased cardiac CT-1 and Gal-3 expression together with cardiac fibrosis and inflammation.
|
30612490 |
2019 |
Cardiac fibrosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In contrast, an inverse association was observed between myocardial Gal-3 expression and cardiac fibrosis in patients with iCMP (<i>r</i>=-0.59; <i>P</i><0.05).
|
28288987 |
2017 |
Cardiac fibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Galectin-3 gene deletion reduced cardiac fibrosis and fibrotic gene profiles and ameliorated cardiac remodeling and dysfunction.
|
30387702 |
2019 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3) is increased in heart failure (HF) and promotes cardiac fibrosis and inflammation.
|
29674526 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Galectin-3 has been proposed as a novel biomarker of heart failure and cardiac fibrosis, and may also be associated with fibrosis of other organs such as the kidney.
|
28865675 |
2018 |